Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 2/20 | 0.51 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4252422 | 0.85 | SMN1; SMN2 (0.77) | PKMSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL7664954 | 0.83 | PKM (0.61) | PKMSMN1; SMN2NPC1RAB9ATDP1 | |
| SCHEMBL4716079 | 0.83 | TDP1 (0.76) | PKMSMN1; SMN2RAB9ATDP1KMT2A | |
| SCHEMBL7659574 | 0.83 | PKM (0.61) | PKMSMN1; SMN2NPC1RAB9ATDP1 | |
| SCHEMBL4717858 | 0.82 | LMNA (0.70) | PKMSMN1; SMN2RAB9AKMT2ALMNA | |
| SCHEMBL14530332 | 0.82 | PKM (0.60) | PKMSMN1; SMN2NPC1RAB9ATDP1 | |
| SCHEMBL3949541 | 0.82 | CNR2 (0.66) | PKMSMN1; SMN2NPC1RAB9ATDP1 | |
| SCHEMBL3948867 | 0.82 | PKM (0.60) | PKMSMN1; SMN2NPC1RAB9ATDP1 | |
| SCHEMBL3963711 | 0.82 | POLB (0.71) | SMN1; SMN2KMT2ALMNATSHRALDH1A1 | |
| SCHEMBL7661174 | 0.82 | PKM (0.60) | PKMSMN1; SMN2NPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020111369-A1 | Aryl sulfonic acids and derivatives as FSH antagonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-08-15 | — | — | US | disclosed |
| US-6355633-B1 | CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-12 | — | — | US | disclosed |
| WO-2000058277-A1 | ARYL SULFONIC ACIDS AND DERIVATIVES AS FSH ANTAGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111369-A1 | Aryl sulfonic acids and derivatives as FSH antagonists | FSHR, GNRHR, LHCGR | PKM 4553/4885SMN1; SMN2 2927/4885NPC1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.